Molecular structure pattern

Lung Cancer References

Last updated: 26 October 2026
Reviewed by
  1. Jhun BW, Park HY, Jeon K, et al. Nodal stations and diagnostic performances of endobronchial ultrasound-guided transbronchial needle aspiration in patients with non-small cell lung cancer. J Korean Med Sci. 2012 Jan;27(1):46-51. doi: 10.3346/jkms.2012.27.1.46. Accessed 15 Oct 2012. PMID: 22219613
  2. Blood Test Detects Lung CancerA blood test that detects a combination of proteins can distinguish between early lung cancer and noncancerous lung nodules, according to a study published in Science Translational Medicine. The two types of nodules are currently difficult to distinguish using imaging. The test showed a 90% negative predictive value in a study of 104 patient samples from three clinical sites. Further validation on 37 samples from a single site showed a 94% negative predictive valueCancer Network; 2013 Oct22 Oct 2013http://www.cancernetwork.com/lung-cancer/blood-test-detects-lung-cancer
  3. MedWormhttp://www.medworm.com/rss/index.php/Cancer-%26-Oncology/6/http://www.medworm.com/rss/medicalfeeds/specialities/Cancer-Oncology.xml
  4. MedWorm http://www.medworm.com/rss/index.php/Respiratory-Medicine/40/ http://www.medworm.com/rss/medicalfeeds/specialities/Respiratory-Medicine-News.xml
  5. Eastern Cooperative Oncology Group. ECOG performance status. http://ecog.dfci.harvard.edu/. Accessed 07 Jul 2010.
  6. Ministry of Health Singapore. Cancer Screening. MOH clinical practice guideline. MOH (Singapore). http://www.moh.gov.sg/. Feb 2010. Accessed 02 Jul 2010.
  7. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 5.2026. NCCN. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. 13 Mar 2026. Accessed 01 Apr 2026.
  8. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: adult cancer pain. Version 2.2016. NCCN. https://www.nccn.org/. Mar 2016. Accessed 16 Sep 2016.
  9. Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest. 2017 Jan;151(1):193-203. doi: 10.1016/j.chest.2016.10.010. PMID: 27780786
  10. Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017 Oct;35(30):3484-3515. doi: 10.1200/JCO.2017.74.6065. PMID: 28806116
  11. National Institute for Health and Clinical Excellence. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer. NICE. http://www.nice.org.uk/. Jul 2015.
  12. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017 Jul;284(1):228-243. doi: 10.1148/radiol.2017161659. PMID: 28240562
  13. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. European Society of Medical Oncology. https://www.esmo.org/. Sep 2019.
  14. Wu YL, Planchard D, Lu S, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019 Feb;30(2):171-210. doi: 10.1093/annonc/mdy554. PMID: 30596843
  15. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: lung cancer screening. Version 1.2026. NCCN. https://www.nccn.org/. 16 Sep 2025. Accessed 12 Apr 2021.
  16. Clinical Therapy Advisor. Non-small cell lung cancer treatment regimens. Clinical Therapy Advisor. https://www.cancertherapyadvisor.com/. 23 Oct 2020. Accessed 12 Apr 2021.
  17. Clinical Therapy Advisor. Small cell lung cancer treatment regimens. Clinical Therapy Advisor. https://www.cancertherapyadvisor.com/. 03 Aug 2020. Accessed 12 Apr 2021.
  18. Yang P. National lung cancer screening program in Taiwan: The TALENT study. J Thorac Oncol. 2021;16(3S):S58-S62. https://www.jto.org/.
  19. Lee H. Medical thoracoscopy (pleuroscopy): Diagnostic and therapeutic applications. UpToDate. https://www.uptodate.com/. 14 Jul 2021.
  20. Thomas KW, Gould MK, Naeger D. Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer . UpToDate. https://www.uptodate.com/. 21 Jun 2022.
  21. Thomas KW, Gould MK. Procedures for tissue biopsy in patients with suspected non-small cell lung cancer. UpToDate. https://www.uptodate.com/. 02 Jun 2022.
  22. Weinberger SE, McDermott S. Diagnostic evaluation of incidental pulmonary nodule. UpToDate. https://www.uptodate.com/. 24 Mar 2022.
  23. Yu MH, Hoffe SE. Epidemiology, clinical presentation, and diagnosis of bone metastasis in adults. UpToDate. https://www.uptodate.com/. 25 Oct 2021.
  24. Passaro A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022 May;33(5):466-487. doi: 10.1016/j.annonc.2022.02.003. PMID: 35176458
  25. Stevenson MM. Non-small cell lung cancer (NSCLC) treatment protocols. Medscape. https://reference.medscape.com/. 29 Feb 2024.
  26. Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol. 2022 Mar;17(3):362-387. doi: 10.1016/j.jtho.2021.11.003. PMID: 34808341
  27. Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol. 2024 May:JCO2400581. doi: 10.1200/JCO.24.00581. PMID: 38819031
  28. Zhang PX, Liu FJ, Wang DQ, et al. A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer. J Clin Oncol. 2024 May;42(16):8098. https://doi.org/10.1200/JCO.2024.42.16_suppl.8098.
  29. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021 Feb;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. PMID: 33581821
  30. Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021 May;7(5):709-717. doi: 10.1001/jamaoncol.2021.0366. PMID: 33792623
  31. Markham A. Savolitinib: first approval. Drugs. 2021 Sep;81(14):1665-1670. doi: 10.1007/s40265-021-01584-0. PMID: 34455538
  32. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): non-small cell lung cancer. Version 7.2025. NCCN. https://www.nccn.org/. 10 Jul 2025.
  33. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): small cell lung cancer. Version 2.2026. NCCN. https://www.nccn.org/. 16 Sep 2025.
  34. National Medical Products Administration (NMPA). The National Medical Products Administration approved the marketing of savolitinib tablets. NMPA. https://www.nmpa.gov.cn/. 23 Jun 2021.
  35. Zer A, Ahn MJ, Barlesi F, et al; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. Ann Oncol. 2025 Aug:S0923-7534(25)00923-8. doi: 10.1016/j.annonc.2025.08.003. PMID: 40885528
  36. Fang W, Wu L, Meng X, et al. Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC. N Engl J Med. 2026 Jan;394(1):13-26. doi: 10.1056/NEJMoa2512071. PMID: 41124220
  37. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): non-small cell lung cancer. Version 9.2025. NCCN. https://www.nccn.org/. 22 Sep 2026.
  38. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): small cell lung cancer. Version 1.2027. NCCN. https://www.nccn.org/. 01 Jul 2026.
  39. Shaw AT, Solomon BJ, Felip E, et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study. Ann Oncol. 2026 Sep;37(9):1242-1252. doi: 10.1016/j.annonc.2026.05.692. PMID: 42217582